What's in Providence Health & Services's pipeline?

Providence Health & Services has 19 drugs in our index: 4 marketed, 0 filed, 0 in Phase 3, 5 in Phase 2, 10 in Phase 1.

Which companies overlap with Providence Health & Services's portfolio?

Top competitors by shared drug class: Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud, Gan and Lee Pharmaceuticals, USA.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/providence-health-services.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Providence Health & Services — Portfolio Competitive Intelligence Brief

Providence Health & Services pipeline: 4 marketed, 0 filed, 0 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 5 Phase 2 10 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
cetrizine	cetrizine	marketed			Other
Switching to NPH insulin	Switching to NPH insulin	marketed	Intermediate-acting insulin	Insulin receptor	Diabetes
Continuation of insulin glargine	Continuation of insulin glargine	marketed	Long-acting basal insulin	Insulin receptor	Diabetes
ACTH	ACTH	marketed	Corticotropin; peptide hormone	Melanocortin-2 receptor (MC2R)	Endocrinology; Immunology; Rheumatology

Therapeutic area mix

Diabetes · 2
Endocrinology; Immunology; Rheumatology · 1
Oncology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Novo Nordisk A/S · 2 shared drug classes
Sanofi · 2 shared drug classes
Eli Lilly and Company · 1 shared drug class
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · 1 shared drug class
Gan and Lee Pharmaceuticals, USA · 1 shared drug class
Geropharm · 1 shared drug class
Life for a Child Program, Diabetes Australia · 1 shared drug class
Federation Francophone de Cancerologie Digestive · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Providence Health & Services:

Cite this brief

Drug Landscape (2026). Providence Health & Services — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/providence-health-services. Accessed 2026-05-16.